Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 1.00 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30064828 | 1.00 | RXFP1 (1.00) | RXFP1EPHX1KMT2AALDH1A1KDM4E | |
| SCHEMBL25946008 | 0.89 | RXFP1 (0.80) | RXFP1EPHX1KMT2AALDH1A1KDM4E | |
| SCHEMBL30881878 | 0.89 | RXFP1 (0.80) | RXFP1EPHX1KMT2AALDH1A1KDM4E | |
| SCHEMBL1978079 | 0.83 | RXFP1 (0.71) | RXFP1EPHX1KMT2AALDH1A1KDM4E | |
| SCHEMBL1900214 | 0.80 | RXFP1 (0.66) | RXFP1KMT2AALDH1A1KDM4EMAPT | |
| SCHEMBL1803952 | 0.79 | RXFP1 (0.66) | RXFP1EPHX1KMT2AALDH1A1KDM4E | |
| SCHEMBL590479 | 0.79 | RXFP1 (0.66) | RXFP1KMT2AKDM4EMAPTPOLB | |
| SCHEMBL13483433 | 0.79 | RXFP1 (0.66) | RXFP1EPHX1KMT2AALDH1A1KDM4E | |
| SCHEMBL29124130 | 0.79 | EPHX1 (0.73) | RXFP1EPHX1KMT2AALDH1A1KDM4E | |
| SCHEMBL5657172 | 0.78 | RXFP1 (0.64) | RXFP1EPHX1KMT2AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630566-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| US-12377077-B2 | Methods and formulations to treat mitochondrial dysfunction | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2025-08-05 | — | — | US | disclosed |
| US-20240309020-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2024-09-19 | — | — | US | disclosed |
| US-11964989-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2024-04-23 | — | — | US | disclosed |
| CN-114615981-B | KRAS G12D inhibitors | 米拉蒂治疗股份有限公司 | 2024-04-12 | — | — | CN | disclosed |
| US-20230279025-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230279025-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2023-09-07 | — | — | US | disclosed |
| EP-4209492-A1 | COMPOUND FOR TREATING THROMBOTIC DISEASES | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2023-07-12 | — | — | EP | disclosed |
| US-20230077225-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. | 2023-03-09 | — | — | US | disclosed |
| US-11548888-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20170197968-A1 | Compositions and Methods for Inhibiting BMP | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-07-13 | — | — | US | disclosed |
| US-20170197968-A1 | Compositions and Methods for Inhibiting BMP | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-07-13 | — | — | US | disclosed |
| US-20170197968-A1 | Compositions and Methods for Inhibiting BMP | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-07-13 | — | — | US | disclosed |
| WO-2016011019-A1 | COMPOSITIONS AND METHODS FOR INHIBITING BMP | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2016-01-21 | — | — | WO | disclosed |
| WO-2016011019-A1 | COMPOSITIONS AND METHODS FOR INHIBITING BMP | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2016-01-21 | — | — | WO | disclosed |
| US-20040029937-A1 | Benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents | NEUROSEARCH A/S. | 2004-02-12 | — | — | US | disclosed |
| US-6624186-B2 | Modulators of SKCa, IKCa and BKCa channels. | NEUROSEARCH A/S (DK) | 2003-09-23 | — | — | US | disclosed |
| US-20020055526-A1 | Benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents | NEUROSEARCH A/S (DK) | 2002-05-09 | — | — | US | disclosed |
| EP-1144387-A1 | NEW BENZIMIDAZOLONE-, BENZOXAZOLONE-, OR BENZOTHIAZOLONE DERIVATIVES AS ION CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000034248-A1 | NEW BENZIMIDAZOLONE-, BENZOXAZOLONE-, OR BENZOTHIAZOLONE DERIVATIVES AS ION CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2000-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029937-A1 | Benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents | KCNJ2, KCNJ1, KCNJ11 | RXFP1 2774/4885EPHX1 2408/4885KMT2A 1301/4885 |
| US-20230279025-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | RXFP1 2372/4885EPHX1 1883/4885KMT2A 1839/4885 |
| US-20230077225-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | RXFP1 2325/4885EPHX1 1815/4885KMT2A 1755/4885 |
| US-12630566-B2 | KRas G12D inhibitors | KRAS, NRAS, HRAS | RXFP1 2456/4885EPHX1 1208/4885KMT2A 2950/4885 |
| US-20170197968-A1 | Compositions and Methods for Inhibiting BMP | BMP1, BMP2, BMPR2 | RXFP1 868/4885EPHX1 1661/4885KMT2A 3937/4885 |
| US-11548888-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | RXFP1 1791/4885EPHX1 2167/4885KMT2A 2081/4885 |
| US-12377077-B2 | Methods and formulations to treat mitochondrial dysfunction | AK2, PCK2, CS | RXFP1 1833/4885EPHX1 4140/4885KMT2A 3848/4885 |
| US-20020055526-A1 | Benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents | KCNJ2, KCNJ1, KCNJ11 | RXFP1 2774/4885EPHX1 2408/4885KMT2A 1301/4885 |
| US-11964989-B2 | KRas G12D inhibitors | KRAS, NRAS, HRAS | RXFP1 1732/4885EPHX1 2454/4885KMT2A 2336/4885 |
| US-20240309020-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | RXFP1 2325/4885EPHX1 1815/4885KMT2A 1755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.